Tecvayli monotherapy significantly reduces disease progression and mortality in relapsed or refractory multiple myeloma patients, showing a 71% reduction in progression risk and 40% in mortality risk.
CHICAGO -- Adding a novel cereblon E3 ligase modulation (CELMoD) drug to a standard multiple myeloma regimen significantly improved progression-free survival (PFS) in a vulnerable population of ...
MULTIPLE myeloma ICU survival has improved in recent years, with better adjusted one year outcomes despite greater illness ...
Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for ...
Joaquin Duato, chairman and CEO of Johnson and Johnson, speaks at the Punchbowl News Conference at Union Station on March 10, 2026 in Washington, DC. Johnson and Johnson co-sponsored the conference to ...
Black and American Indian/Alaska Native communities have the highest cancer rates of any racial or ethnic group in the U.S.
Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026. These trials show meaningful progress in RRMM. Credit: Nemes Laszlo / Shutterstock.com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results